Sign inCreate account

Report workspace tools

NCT00089791COMPLETEDanonymous

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Postmenopausal Osteoporosis

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

placebo, Denosumab

Source & freshness

Source record

NCT ID

NCT00089791

Original source

ClinicalTrials.gov

Source last updated

Nov 08, 2022

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00089791

Title

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

Osteoporosis

Modality normalized

monoclonal antibody

Target raw

Postmenopausal Osteoporosis

Target normalized

Postmenopausal Osteoporosis

Interventions

placebo, Denosumab

Public preview

Source record

The FREEDOM trial evaluated the efficacy and safety of Denosumab, a monoclonal antibody, in reducing fractures in postmenopausal women with osteoporosis. Conducted by Amgen, the study enrolled 7,808 participants and demonstrated significant fracture risk reduction, positioning Denosumab as a competitive treatment option in the osteoporosis market.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00089791

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The FREEDOM trial evaluated the efficacy and safety of Denosumab, a monoclonal antibody, in reducing fractures in postmenopausal women with osteoporosis. Conducted by Amgen, the study enrolled 7,808 participants and demonstrated significant fracture risk reduction, positioning Denosumab as a competitive treatment option in the osteoporosis market.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 08, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00089791

Indication

Osteoporosis

Modality

monoclonal antibody

Target

Postmenopausal Osteoporosis

Intervention

placebo, Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.